1. Investor Presentation
Pressure BioSciences, Inc.
(
(OTCQB: PBIO)
)
Discovery Starts
with Sample Preparation™
August 10, 2012
g ,

2. Forward Looking Statements
This
Thi presentation may contain f
t ti t i forward l ki statements
d looking t t t
that reflect management’s current views and opinions as
to the status of the Company’s products, technology and
other future events and operations These statements are
operations.
neither a promise nor guarantee, but involve risks and
uncertainties that could cause actual results to differ
materially from those anticipated or indicated Investors
indicated.
are cautioned that any forward looking statements should
be considered in light of such risks and uncertainties
including, without limitation, those detailed in the
g, ,
Company’s filings with the
Securities and Exchange Commission.
2

3. Key Investment Highlights
• Pressure Cycling Technology (PCT): Powerful, Enabling, Patented
• $6 Billion M k t O
Billi Market Opportunity: Bi l i l Sample Preparation
t it Biological S l P ti
• Focus on Sample Preparation for Biomarker Discovery & Forensics
• PCT Products Offer Si ifi
P d t Off Significant Advantages O
t Ad t Over Competitive Methods
C titi M th d
• Proven Technology: ~ 215 Installations in ~150 Marquee Laboratories
• E i ti
Existing and New Products Offer Significant Growth Opportunity
dN P d t Off Si ifi tG th O t it
• Attractive “Razor/Razorblade” Business Model
• O
On-going Discussions with Large Potential Strategic Partners
i Di i ith L P t ti l St t i P t
• Experienced Management Team and Board of Directors
• F
Favorable M k t V l ti
bl Market Valuation f th I t
for the Investor
• Commercialization Program Rollout in 2012
3

4. Company Background
• Formed Sept 2004 - Sale of Boston Biomedica (BBII)
( )
• Started Significant Operations in 2006
• OTCQB: PBIO
• Twelve (12) Full-time Employees
• Strong Management Team and Board of Directors
S f
• Focused on the Development and Commercialization of
PCT-based Instruments and Consumables for the Preparation
C C p
of Biological Samples for Research Laboratories
• Strong IP - 24 Issued PCT Patents with More Pending
4

5. Experienced Senior Management & Board
Management
• Mr. Richard T. Schumacher, President & CEO
Boston Bi
B t Biomedica (CEO) P
di (CEO); Panacos Ph
Pharma (President); C t f Bl d
(P id t) Center for Blood
Research (CBR Labs - Harvard Medical School) -General Manager
• Dr. Edmund Y. Ting, Senior Vice President of Engineering
Avure Technologies (
g (CSO); Flow Int’l; Grumman Aerospace; MIT (Ph.D.)
); ; p ; ( )
• Dr. Alexander V. Lazarev, Vice President of R&D
Proteome Systems; Genomic Solutions; ESA; University of Kazan (Ph.D.)
• Dr Nathan P. Lawrence, Vice President of Sales & Marketing
Dr. P Lawrence
Boston Biomedica; BD; Gene-Trak Systems; Yale University (Ph.D.)
• Mr. Joseph Damasio, Vice President of Finance & Adm.
PricewaterhouseCoopers; NEN Life Sciences; Boston College (MBA)
Board
• Jeffrey N. Peterson, Board Chairman & Nominations Committee Chair
• Kevin A. Pollack, Esq., Audit Committee Chair
• Vito J. Mangiardi, Compensation Committee Chair
• R. Wayne Fritzsche, SAB Member Liaison
• Richard T. Schumacher
5

6. Past Accomplishments – CEO and Chairman
Company Role Top Market Cap Outcome
Schumacher
Pressure BioSciences (OTCQB: PBIO) Founder, CEO
Founder CEO, Director
Boston Biomedica (Nasdaq BBII) Founder, CEO, Director ~$120 million Sold
Panacos Pharma (Nasdaq PANC) Co-Founder, Director ~$650 million Sold
Trinity Biotech (Nasdaq TRIB) Founding Group ~$250 million
$250 Going Strong
CBR Laboratories (Harvard Med) Founding Group N/A N/A
Fritzsche *
Intelligent Medical Imaging Co-Founder, Chairman ~$280 million Sold
Immune Response Co-Founder ~$750 million Now OCHT.PK
Opexa Ph
O Pharma (Nasdaq OPXAW)
(N d Co-Founder
C F d >$25 million
$25 illi Sold
S ld
Cytogen Co-Founder >$100 million Sold
Occulogix Co-Founder >$50 million Sold
* Mr. Fritzsche was also the founder or co-founder of approximately 20 additional companies
and has raised more than $120 million for these companies over the years.
6

7. Value Proposition – Sample Prep Market
• Analysis of DNA, RNA, Proteins, & Lipids (“biomolecules”) is
Crucial to the Development of New Diagnostics & Therapeutics
• Sample Preparation is Required Prior to Virtually All Analyses
• Current Sample Preparation Methods are Highly Inadequate: bottleneck
• PCT Offers Many Clear Advantages Over Current Competitive Products
• Current Target: Life Sciences Research Market – minimal regulatory
• PBI Holds 24 Issued PCT Patents in Multiple Sample Prep Applications
• Early Traction…about 200 PCT Systems installed through Q4 2011
y y g
• $6 Billion* Market Opportunity for Sample Preparation Products
~ 500K Scientists in ~ 80K Labs WW require some sample preparation**
* Strategic Directions Int’l; **The Emmes Group
7

8. Release Important Biomolecules bygy (PCT)
Pressure Cycling Technology ( Lysis
p y g y Cell y )
8

9. Sample Input Quality = Sample Result Quality
Scientific research can be broken down to three key elements:
sample preparation, analysis, & data reduction/interpretation
“Discovery Starts with Sample Preparation”
9

10. Competitive Landscape
Mostly Commodity Products Through Catalogue Sales
• Mortar & Pestle
• Dounce homogenizer (glass on glass)
• Potter-Elvenhjem homogenizer (Teflon on glass)
• Enzymatic Digestion
• Polytron shearing homogenizers
• Blenders
• Bead Beating
• Sonication
• Repeated Freeze/Thaw cycles
• French Press (≤ 2000 PSI)
10

11. PCT Sample Preparation System
Barocycler™
NEP2320 Barocycler™ NEP3229 PULSE Tube
MicroTubes PCT-dependent Kits
11

12. Selected Marquee Customers (40 of 150)
• Amgen • Thermo Fisher
• Biogen • Target Discovery
• Lilly
y • Battelle Memorial Institute
• Novartis • Harvard Medical School
• Monsanto • Harvard School of Public Health
• BM Squibb • Rockefeller University
• Merck • University of New Hampshire
y p
• Centocor • Barnett Research Inst (NEU)
• Takeda Pharmaceuticals • UCLA
• Momenta Pharmaceuticals • UC - San Diego
• US Army y • UC - Davis
• FBI • Lawrence Livermore
• Food and Drug Administration • Stanford University
• US Department of Agriculture • University of North Texas
• National Institutes of Health • Mississippi State
• Armed Forces Inst. of Pathology • Montana State
• Centers for Disease Control • Lawrence Berkeley
• USAMRIID • University of Kentucky
• Beth Israel Deaconess Hospital • Florida Int’l University
• Burnham Research Institute • UMASS – Boston
12

13. Current PCT Products & Product Pipeline
• PCT Sample Preparation System 2012: Aggressive
(Barocycler NEP3229 & NEP2320) Commercialization
• The PCT Shredder SG3 Just Released
• Barocycler HUB440 Just Released
• FFPE System – proteins, DNA/RNA 2013
• PCT-based HT (48 - 384 well format) 2014
• XstreamPCT™ HPLC Digestion System 2014
13

14. PCT Sample Preparation System
Barocycler™
NEP2320 Barocycler™ NEP3229 PULSE Tube
MicroTubes PCT-dependent Kits
14

15. Product Pipeline (2011 Release)
The Shredder
SG3
Low Shear, Mechanical,
Homogenization Device
• Long lasting lithium
rechargeable batteries
• Paddle for convenient
pressure setting
• Pressure levels:
15, 30, 45 lbs. Force
• Uses PCT PULSE and
Shredder Tubes
• Heavy Duty, Robust Driver
15

16. Product Pipeline (2011 Release)
The Barocycler HUB440
High P
Hi h Pressure Generator
G t
• Compact
p
• Portable
• Versatile
• Manual or
Computer Controlled
• Pressures to 58Kpsi
State-of-the-Art
High Pressure Generator
for Multiple Bioscience Applications
16

17. Product Pipeline (2012 Release)
The Barocycler NEP-FFPE
y
• 1 Billion Stored Samples WW
• 6x More Non-redundant Proteins
from FFPE Aorta
Dr. J. Van Eyk, et al., J. Hopkins
• 2x More Unique Proteins from
FFPE Mouse Liver
Dr. C. Fowler, et al., AFIP
PCT-enhanced Protein Extraction from
F
Formalin-Fixed P
li Fi d Paraffin-Embedded (FFPE) S
ffi E b dd d l
Samples
AVAILABLE 2013
17

18. Product Pipeline (2013 Release)
XstreamPCT™ Digestion Module
Automated, In-line, On-demand PCT-enhanced Digestion
A t t d I li O d d PCT h d Di ti
• Significantly Reduced
Protein Digestion Time
• Increased Membrane
Protein Recovery
• Rapid & Less Costly
De-glycosylation
• Excellent
Reproducibility
The First Module in PBI’s Extreme PCT (35,000 psi) HPLC Platform
AVAILABLE 2014 18

19. Product Pipeline (2013 Release)
The Barocycler HT Multiwell (48/96/384)
Process 48, 96, or 384
Samples with the
•S f
Safety
• Speed
• Quality
• Versatility
• Reproducibility
of PCT
For High Throughput PCT-enhanced Biomolecule
Extraction & Accelerated Enzymatic Digestion
AVAILABLE 2014
19

20. Financial Data
Historical Revenue Data
• 2009 $1,200,000
• 2010 $1,300,000
$1 300 000
• 2011 $1,000,000
Selected Data Through March 31, 2012
• Cash/Cash Equivalents ~$ 0.2 million
• Inventory ~$ 1.0 million
• Debt (unsecured) ~$ 0.06 million
Selected Data Through July 13, 2012
• Price per Share $0.42
• Total Common 10.4
10 4 million
• Total Preferred (com equiv) 0.8 million
Total Shares OS 11.2 million
• Market Cap (Com/Prfd)
p( ) $4.7 million
$
20

21. Capitalization Table
As of July 13, 2012
In C
I Common Stock Equivalents (numbers are approximate)
St k E i l t ( b i t )
Description Number
Common Shares Outstanding 10,400,000
Convertible Preferred Stock D 800,000
Total Common Stock Equivalents 11,200,000
Warrants (Weighted Average Strike Price of $1.06) 5,100,000
Stock Options (Weighted Average Strike Price of $2 17)
$2.17) 1,700,000
1 700 000
Total Warrants and Options 6,800,000
Total Proceeds from Exercise of Warrants and Options $9,100,000
21

22. PBI Sample Preparation Focus Areas
Biomarker Discovery
Dr. Andreas Huhmer – Thermo Fisher Scientific
…advantages of speed and quality using PCT in mass spec workflow
Dr. Michael Alterman – Tumor Vaccines and Biotechnology Branch, CBER, FDA
…improved influenza vaccine quality using PCT in mass spec workflow
Dr. Alexander Ivanov – Harvard School of Public Health
…improved protein identification using PCT in mass spec workflow
improved
Dr. Luke Schneider, Target Discovery, Inc.
…improved membrane protein recovery in ovarian cancer studies using PCT in mass spec workflow
Forensics ***
Dr. Henry C. Lee, the Henry C. Lee Institute of Forensic Science
…evaluation of PCT in the recovery and detection of DNA in difficult forensic samples
Dr. Bruce McCord, Florida International University
…improved processing of forensic (rape kit) samples using PCT
Dr. Bruce Budowle, Health Science Center, University of North Texas
…improved detection of DNA in forensic samples using PCT
Pathology (FFPE Samples)
Dr. Jeff Mason and Dr. Carol Fowler, Armed Forces Institute of Pathology
...improved processing of FFPE (histology) samples using pressure
Dr. Jennifer Van Eyk, Johns Hopkins School of Medicine
…improved recovery of aorta proteins from FFPE samples using PCT 22

23. Professor Wayne Hubbell - UCLA
Distinguished Professor of
Chemistry & Biochemistry,
and Jules Stein Professor at
UCLA
"Protein flexibility is the new frontier in understanding protein
Protein
function and regulation. The study of proteins under pressure
has great ability to reveal salient features of protein flexibility,
and hence provide new insights into p
p g protein function and
rational drug design. In my opinion, high pressure will
play a central role in the discovery process that lies ahead in
the exciting field of protein science, and the PBI hardware will
make major contributions to this field.”
December 7, 2011 23

24. Dr. Henry C. Lee
Professor of Forensic Science and
founder of the Forensic Science
Program at the University of New
Haven; founder of the HC Lee
Institute of Forensic Sciences; and
former C
f Commissioner of Public
i i f P bli
Safety for the State of Connecticut.
“We are excited about this opportunity to collaborate with
“
Pressure BioSciences to examine the potential applications of
their PCT Platform in improving the collection of forensic
evidence,
evidence particularly DNA in several important areas of
DNA,
forensics…such collaborations not only provide new, effective
technologies for forensic DNA testing of samples that have
been difficult or unsuitable using today’s standard techniques
today s techniques,
but can also provide new and more effective ways to
reexamine old biological evidence in cold cases.”
24

25. News of Interest - 2012
PBI Expands Sales Reach with Distribution Agreements for China, Australia, and Others
PBI Closes First Tranche ($600K) of a $1.2 Million Above-Market Private Placement
PBI Reduces Board of Directors from Eight to Five; Adds Veterans Mangiardi and Pollock
Ironridge BioPharma Invests $500K in PBIO at $1.02/share (no warrants, etc.)
PBI’s
PBI’ PCT Platform Key to TDI’s Planned Ovarian Cancer Testing Service
Pl f K TDI’ Pl dO i C T i S i
Collaboration with Dr. Henry C. Lee and the HC Lee Institute of Forensic Science
Dr. W. Hubbell (UCLA) Presents Data Citing Proteomics Enhancement with PCT
ubbe (UC ) ese ts ata C t g oteo cs a ce e t t C
European Sales Reach Expanded with Distribution Agmt for Benelux Countries
PBI Reports 2011 Financial Results: 22% revenue increase in Q42011 vs.
Q42010; 66% revenue increase in 2H2011 vs 1H2011
vs.
$800,000 Private Placement Closed – transaction priced at market
Significant Progress Cited Using PCT in Processing of Sexual Assault Samples
PBI and DIGI Labs Announce Global Co-Marketing/Selling/Development Agreement
25

26. 2012 Potential Drivers
• Aggressive Commercialization Program for PCT Products
• Expansion of Distribution Network (3 to ~20 countries)
• Expansion of PBI Sales (3 to 8) & Marketing (1 to 3) Teams
p ( ) g( )
• Expansion of Strategic Partners (2 to 4, at a minimum)
• Expected Completion of Significant Funding (up to 2 years cash)
• Measurable Progress on FFPE, XstreamPCT, HT Microwell
Instruments and Consumables
• Continuation of Aggressive IR (Awareness) Campaign
• Significant Revenue Run-rate Increase Throughout 2012
Run rate
26

27. Key Investment Highlights
• Pressure Cycling Technology (PCT): Powerful, Enabling, Patented
• $6 Billion M k t O
Billi Market Opportunity: Bi l i l Sample Preparation
t it Biological S l P ti
• Focus on Sample Preparation for Biomarker Discovery & Forensics
• PCT Products Offer Si ifi
P d t Off Significant Advantages O
t Ad t Over Competitive Methods
C titi M th d
• Proven Technology: ~ 215 Installations in ~150 Marquee Laboratories
• E i ti
Existing and New Products Offer Significant Growth Opportunity
dN P d t Off Si ifi tG th O t it
• Attractive “Razor/Razorblade” Business Model
• O
On-going Discussions with Large Potential Strategic Partners
i Di i ith L P t ti l St t i P t
• Experienced Management Team and Board of Directors
• F
Favorable M k t V l ti
bl Market Valuation f th I t
for the Investor
• Commercialization Program Rollout in 2012
27